Gilead Sciences, Inc. (GILD)

125.98 +0.79 (+0.63%) USD  |  NASDAQ  |  Dec 24, 12:34
More

Gilead Sciences CAPEX To Revenue (TTM)

CAPEX To Revenue (TTM) Chart

View CAPEX To Revenue (TTM) for GILD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View CAPEX To Revenue (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

CAPEX To Revenue (TTM) Range, Past 5 Years

View CAPEX To Revenue (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

CAPEX To Revenue (TTM) Benchmarks

View CAPEX To Revenue (TTM) Benchmarks
Start Trial
Amgen, Inc. Upgrade
Johnson & Johnson Upgrade
Eli Lilly & Co. Upgrade
Merck & Co., Inc. Upgrade
Regeneron Pharmaceuticals, Inc. Upgrade